Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma.

Publication date: Jul 11, 2023

Concepts Keywords
Cobimetinib BRAF
French Cost-effectiveness
Mutant Economic analysis
Survival Encorafenib


Type Source Name
drug DRUGBANK Encorafenib
drug DRUGBANK Binimetinib
disease MESH melanoma
pathway KEGG Melanoma
drug DRUGBANK Dabrafenib
drug DRUGBANK Trametinib
drug DRUGBANK Vemurafenib
drug DRUGBANK Cobimetinib

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *